Last reviewed · How we verify
amoxil capsule
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including otitis media, sinusitis, and respiratory tract infections, Urinary tract infections, Skin and soft tissue infections.
At a glance
| Generic name | amoxil capsule |
|---|---|
| Also known as | amoxicillin |
| Sponsor | China Academy of Chinese Medical Sciences |
| Drug class | Beta-lactam antibiotic (penicillin-type) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial lysis. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria. The drug is commonly used to treat infections caused by susceptible organisms.
Approved indications
- Bacterial infections including otitis media, sinusitis, and respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Streptococcal pharyngitis
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / anaphylaxis
- Abdominal pain
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Effect of Antibiotics on Enteric Neurons and Glia (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin (PHASE1)
- Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward (PHASE3)
- The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxil capsule CI brief — competitive landscape report
- amoxil capsule updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI